[16] Hiransuthikul A, Janamnuaysook R, Himmad K, et al. Drug‐drug interactions between feminizing hormone therapy and pre‐exposure prophylaxis among transgender women: the iFACT study[J]. Journal of the International AIDS Society, ...
NIH launches first large trial of a long-acting injectable drug for HIV prevention Dec 20, 2016 Bimonthly, injected PrEP beats daily pill in warding off HIV: Study Aug 12, 2021 Long-acting injectable form of HIV prevention outperforms daily pill in NIH study Jul 7, 2020 Long-acting ...
Methods ART-naive patients in the FHDH ANRS CO4 cohort who started cART containing TDF/FTC plus either ATV/r or another recommended third drug (LPV/r, f-AMP/r or EFV) after 31/12/2003 and at least 12 month before the closing date of the database were analyzed. Multivariable Cox's ...
P081The cost of cost-saving HIV drug switches in a small DGH HIV unit Results Eleven patients switched successfully from Kivexa to generic abavavir/lamivudine. Fifteen switched from Atripla to Truvada/efavirenz. Of these, four ... K Street,C Priestley,S Scofield - 《Sexually Transmitted Infecti...
Van Lunzen J, Fatkenheuer G, Lutz T, Klauke S, Mauss S, Knechten H, et al. Effi- cacy and tolerability of TDF/FTC-containing first line HAART in clinical practice: 2 year data from the German outpatient cohort. In: 9th International Congress on Drug Therapy in HIV Infection. 2008....
Six patients ceased TVD because of drug-related nephrotoxicity. The only factors associated with nephrotoxicity were age, baseline weight and cGFR. Simplification from TDF-3TC to TVD was associated with a decrease in cGFR, with a low prevalence of nephrotoxicity at 48 weeks.R. Palacios...
doi:10.1186/1758-2652-13-S4-P4NEVIRAPINERITONAVIRHIV infectionsTHERAPEUTICS7-11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UKDeJesus, EMills, ABhatti, LConner, CStorfer, SJournal of the International AIDS Society...
Van Lunzen J, Fatkenheuer G, Lutz T, Klauke S, Mauss S, Knechten H, et al. Effi- cacy and tolerability of TDF/FTC-containing first line HAART in clinical practice: 2 year data from the German outpatient cohort. In: 9th International Congress on Drug Therapy in HIV Infection. 2008....
Presented at the Eleventh International Congress on Drug Therapy in HIV Infection, Glasgow, UK: November 11-15, 2012.Cohen C, Green J, Olivet H, Khanlou H, Burman W, Corales R, et al. (2012) A randomized pilot study of tenofovir/emtricitabine (TDF/FTC) + boosted atazanavir (ATV/r) ...
It was also assessed whether the increase remained stable during FTC/TDF prophylaxis over time; cases with at least 4 ALT determinations were included, representing a total of 21 users, of which only 5 had a stable elevation, suggesting a possible role for the drug as a cause. Conclusions ...